1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.It's not to say that every time I see a good thing or a big rise, I just want to buy it, so I may be chasing high every time.1. Now the market has returned to the human nature stage of opening higher and going lower, opening lower and going higher. I've been watching more emotional outbursts and higher prices, but it happened that the market was calmed down by smashing the market, and everyone was more pessimistic. When I felt that the low price was going to plummet, the main institutions stood up and pulled up.
Today's A-share shrinkage is too obvious. Don't expect to get out of the anti-package, and it is not allowed to do so now. Institutions will definitely exert their strength when the market is calm. Today is the slow cow that meets the above requirements, but when the mood is calm, the quantity will also come down. How to understand it?At this time, institutions will either choose some high dividends or some oversold industry leaders as a defense. Those who want to catch the daily limit and buy and sell in day trading are more likely to lose money.Judging from the rise in these directions, I think it is very simple for investors now. Just do the following:
It's not to say that every time I see a good thing or a big rise, I just want to buy it, so I may be chasing high every time.Because for many institutions, it is unlikely to make a big increase every day at the end of the year, and then create a wave of rapid bull market. Many institutions pursue stability and lock in this year's profit results.The plates were those that opened higher yesterday, and they have been further repaired today. At the end of the year, don't always think about chasing the daily limit, low-level consumer medicine, and the industry's low valuation leader, holding it steadily in the cyclical direction.